ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

AstraZeneca ups portfolio

August 7, 2006 | APPEARED IN VOLUME 84, ISSUE 32

AstraZeneca and Pozen will collaborate to develop fixed-dose combinations of esomeprazole, the active ingredient in AstraZeneca's proton pump inhibitor Nexium, and naproxen, using Pozen's PN technology. The single-tablet product will be used to treat pain and inflammation in patients with arthritis who are at risk of gastric ulcers. Pozen, which will be responsible for filing a New Drug Application in the U.S., will receive a $40 million up-front fee and could gain another $335 million in milestones and royalties on sales.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment